ResMed Given New $46.00 Price Target at Jefferies Group (RMD)
Jefferies Group raised their target price on shares of ResMed (NYSE:RMD) from $40.00 to $46.00 in a research note issued on Friday, AnalystRatings.Net reports. The firm currently has a “hold” rating on the stock. Jefferies Group’s price objective indicates a potential downside of 7.16% from the company’s current price.
RMD has been the subject of a number of other recent research reports. Analysts at UBS AG upgraded shares of ResMed from a “neutral” rating to a “buy” rating in a research note to investors on Friday. Separately, analysts at Deutsche Bank downgraded shares of ResMed from a “buy” rating to a “hold” rating in a research note to investors on Friday. They now have a $54.00 price target on the stock, down previously from $58.00. Finally, analysts at Piper Jaffray Cos. raised their price target on shares of ResMed from $54.00 to $59.00 in a research note to investors on Wednesday, October 9th. Nine investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. ResMed has an average rating of “Hold” and a consensus target price of $49.68.
ResMed (NYSE:RMD) opened at 49.55 on Friday. ResMed has a 52 week low of $37.31 and a 52 week high of $52.77. The stock has a 50-day moving average of $48.96 and a 200-day moving average of $46.95. The company has a market cap of $7.039 billion and a P/E ratio of 26.81. ResMed also saw unusually large options trading on Friday. Stock investors acquired 12,526 put options on the stock. This represents an increase of 433% compared to the average daily volume of 2,352 put options.
ResMed (NYSE:RMD) last announced its earnings results on Thursday, October 24th. The company reported $0.56 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.58 by $0.02. The company had revenue of $357.66 million for the quarter, compared to the consensus estimate of $372.28 million. During the same quarter in the prior year, the company posted $0.49 earnings per share. The company’s quarterly revenue was up 5.3% on a year-over-year basis. Analysts expect that ResMed will post $2.56 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which is scheduled for Wednesday, December 18th. Investors of record on Tuesday, November 19th will be paid a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a dividend yield of 2.02%. The ex-dividend date is Friday, November 15th.
ResMed Inc, (NYSE:RMD) is a holding company for the ResMed Group.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.